Skip to main content
Evidence Snapshot

Carbonic anhydrase 3

CHEMBL2885 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2885
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 3 as ChEMBL target CHEMBL2885, mapped to UniProt P07451. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2885
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P07451
Carbonic anhydrase 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Carbonic anhydrase 3 matters

As of 2026-09-14

Carbonic anhydrase 3 is reviewed as Carbonic anhydrase 3 (UniProt P07451); the current evidence base includes 20 approved drugs, 443 compounds, and 92 assays, with lead potency reaching pChEMBL 9.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 20 approved drugs, 443 compounds, and 92 assays for this target. The dominant activity type is KD. CHEMBL19 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL19 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
20 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Carbonic anhydrase 3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07451, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

443
Total Compounds
92
Total Assays
20
Approved Drugs
IC50: 3.0, KI: 279.0, KD: 330.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL19
 9.0 Ki Approved
No preferred name
CHEMBL20
 8.5 Ki Approved
No preferred name
CHEMBL4562296
 8.2 Kd —
No preferred name
CHEMBL4165570
 8.1 Kd —
No preferred name
CHEMBL4170792
 8.1 Kd —

Approved Drugs

Structure Compound First Approval
LACOSAMIDE
CHEMBL58323
 2008
NILOTINIB
CHEMBL255863
 2007
IMATINIB
CHEMBL941
 2001
INDAPAMIDE
CHEMBL406
 1983
METHAZOLAMIDE
CHEMBL19
 1959
ACETAZOLAMIDE
CHEMBL20
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2885